FibroBiologics, Inc. develops fibroblast-based and fibroblast-derived therapies for chronic diseases and regenerative medicine applications. News about FBLG centers on its clinical-stage cell-therapy platform, including CYWC628 for diabetic foot ulcers, CYPS317 for psoriasis, CYMS101 for multiple sclerosis, and related programs in wound healing, disc degeneration, orthopedics, cancer, immune aging, and pulmonary inflammatory conditions.
Company updates commonly cover clinical-trial preparation and drug-product manufacturing, preclinical data from fibroblast spheroids and thymic organoid research, scientific meeting presentations, shareholder communications, quarterly financial results, Nasdaq listing compliance, and capital-planning actions that support development of its fibroblast technology pipeline.
FibroBiologics (FBLG) received European Patent No. 3568465 for methods intended to enhance the regenerative activity of fibroblasts.
The granted claims cover preparing fibroblasts with platelet-rich plasma and one or more cytokines, including FGF-alpha or FGF-beta. They also cover combinations that include a TGF-beta-family cytokine. Additional claims address blood-vessel formation, known as angiogenesis, and spinal disc regeneration. FibroBiologics links the patent to its disc degeneration clinical pathway.
FibroBiologics (FBLG) closed a $0.5 million private placement on September 15, 2026, with its Chief Scientific Officer, Hamid Khoja, Ph.D. The transaction covered 298,508 shares of common stock and accompanying warrants to purchase up to 298,508 additional shares, sold at a combined price of $1.675 per share-plus-warrant unit, calculated from a $1.55 share price and $0.125 per warrant. The warrants are immediately exercisable at $1.55 per share and expire five years from issuance. Gross proceeds are intended for general corporate purposes and working capital. The unregistered securities were issued under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
FibroBiologics (FBLG) received U.S. Patent No. 12,721,866 on September 1, 2026 for therapeutic use of fibroblasts in wound healing.
The patent covers topical administration of 3D spheroid fibroblasts and fibroblast-derived materials, including extracellular vesicles and exosomes, to treat and accelerate healing of acute and chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure wounds, burns, cuts, and abrasions. Preclinical models described in the patent showed wounds treated with fibroblast spheroids and fibroblast-derived materials healed significantly faster than controls in both diabetic and non-diabetic settings.
FibroBiologics (Nasdaq:FBLG) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,716,055 covering methods for treating degenerative disc disease using fibroblast conditioned media. The patent protects approaches that stimulate fibroblasts with opioid receptor antagonists, such as naltrexone, and toll-like receptor agonists to enhance production of regenerative growth factors like EGF.
Conditioned media and components derived from these stimulated fibroblasts may be delivered directly into intervertebral discs or systemically to promote disc regeneration and stimulate proteoglycan synthesis, potentially offering a less invasive alternative to current pain management and surgical treatments. According to FibroBiologics, this patent expands its intellectual property portfolio within disc degeneration, one of its core clinical pathways, and adds to its 270+ issued and pending patents across multiple disease areas.
FibroBiologics (Nasdaq: FBLG) announced the release of the third batch of its investigational drug product CYWC628 and its shipment to Australia to support an ongoing Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs). The batch was manufactured under current Good Manufacturing Practices (cGMP) and passed all required safety and quality tests, enabling its use in the trial.
According to FibroBiologics, the additional drug supply will help clinical sites continue the study, which evaluates safety, tolerability and efficacy of CYWC628 as a topical allogeneic fibroblast cell-based therapy for refractory DFUs. The randomized, multicenter trial compares standard of care plus low- or high-dose CYWC628 to standard of care alone over up to 12 weeks of treatment. The company reported encouraging progress to date and anticipates reporting statistically significant interim primary outcome data in the second half of 2026.
FibroBiologics (Nasdaq: FBLG) announced that on August 25, 2026, Nasdaq confirmed the company has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2). As a result, FibroBiologics is now in compliance with all Nasdaq listing standards and its common shares will continue trading on the Nasdaq Capital Market under the ticker FBLG.
FibroBiologics is a clinical-stage biotechnology company focused on therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, and reports holding more than 270 issued and pending patents.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotech focused on fibroblast-based therapeutics for chronic diseases and human longevity, announced the appointment of legendary sports agent and attorney Leigh Steinberg to its Board of Directors, effective August 24, 2026.
According to FibroBiologics, Steinberg brings five decades of dealmaking experience, a long history of advocacy for brain health and chronic disease awareness, and extensive relationships across sports, medicine, business, and media. He has represented over 300 professional athletes, negotiated more than $4 billion in player contracts, and helped direct over $800 million to charities worldwide. FibroBiologics highlights his work organizing brain health summits since 1994 and his recently launched foundation focused on neurological injury research and awareness as aligned with the company’s human longevity and chronic disease programs.
FibroBiologics (Nasdaq:FBLG) announced that IP Australia has accepted Australian Patent Application No. 2020368344 covering the use of cannabidiol (CBD) as an adjuvant to fibroblast-based cell therapy for the treatment of degenerative disc disease. The application describes methods of co-administering CBD with therapeutically effective fibroblast cells, including fibroblasts differentiated into notochord cells or chondrocytes, to support regeneration of the nucleus pulposus.
The claims also include using CBD to enhance fibroblast regenerative activity, such as boosting production of growth factors like IGF-1 and EGF-1. According to FibroBiologics, the acceptance strengthens its intellectual property position in disc degeneration, adding to its portfolio of 270+ issued and pending patents worldwide.
FibroBiologics (Nasdaq: FBLG) reported preclinical animal data showing cartilage repair within four weeks after a single injection of fibroblast-spheroid-derived chondrocyte spheroids (FSdCS) in induced joint defects. According to FibroBiologics, these in vivo results provide proof of concept for a regenerative approach that aims to repair damaged joints rather than only manage symptoms.
The company highlights a four-day manufacturing process to convert spheroids into chondrocyte spheroids, positioning FSdCS as a potential lower-cost and scalable cell-therapy option compared with conventional timelines. FibroBiologics describes FSdCS as three-dimensional clusters of proliferating cartilage-producing cells designed for direct injection into damaged joints. The data are characterized as preliminary preclinical findings that will guide design of future studies.
FibroBiologics (Nasdaq: FBLG) announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 12,691,147, titled “Methods and Compositions for Treatment of Type 1 Diabetes Using Fibroblasts in Facilitation of Islet Engraftment.” The patent covers methods using fibroblasts to enhance engraftment, survival, and long-term function of transplanted pancreatic islets in Type 1 diabetes.
The technology describes fibroblast-based compositions that improve the microenvironment for transplanted islets, potentially increasing islet viability and donor tissue utilization. FibroBiologics, a clinical-stage biotech focused on fibroblast-based therapies, now holds 270+ issued and pending patents across multiple chronic disease areas.